Vpriv
velaglucerase alfa · Takeda Pharmaceuticals International AG Ireland Branch
AUTHORISED IN THE EUWhat Vpriv is used for
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Vpriv
- Active substance
- velaglucerase alfa
- Disease area
- Gaucher Disease
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB10
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Authorised in the EU since
- 2010
Official information
In the USA
Same active substance: Vpriv
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vpriv used for?
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
What is the active substance in Vpriv?
Vpriv contains velaglucerase alfa.
Who makes Vpriv?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland Branch.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU